The Down Under medical community is abuzz with the introduction of retatrutide, a innovative dual GIP and GLP-1 receptor agonist showing significant results in early trials for addressing obesity. This https://tbookmark.com/story21623108/retatrutide-australia-australia-a-potential-hope-for-weight-management